A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects
NCT ID: NCT03922373
Last Updated: 2019-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
40 participants
INTERVENTIONAL
2018-09-10
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Efficacy and Safety of Benzonatate Soft Capsules for Improving Adult Cough Symptoms
NCT03722914
TCM Differentiation and Treatment Protocol of COVID-19
NCT04306497
Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study
NCT00936013
Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine
NCT02937207
Traditional Chinese Medicine or Low-dose Dexamethasone in COVID-19 Pneumonia
NCT05798195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Benzonatate
Group A: Benzonatate 100mg
Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Group B: Benzonatate 200mg
Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Group C: Benzonatate 400mg
Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group A: Benzonatate 100mg
Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Group B: Benzonatate 200mg
Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Group C: Benzonatate 400mg
Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Male or Female ages 18 through 45 (include 18 and 45).
3\. The male subjects weighed more than 50 kg, the female subjects weighed more than 45kg. Body Mass Index(BMI) between 18 and 28, BMI=Weight(kg)/Height2(m2).
Exclusion Criteria
2\. Abnormal physical examination and abnormal vital signs, and have clinical significance.
3\. Abnormal results of laboratory studies and have clinical significance. 4. Abnormal electrocardiogram and have clinical significance. 5. The hepatitis B surface antigen(HbsAg), hepatitis C antibody, HIV antibody and antigen, Treponema pallidum antibody（TP-Ab）were positive.
6\. Patients with cardiovascular system, urinary system, digestive system, nervous system, respiratory system, mental or immunodeficiency diseases.
7\. Dysphagia or with gastrointestinal history influencing drug absorption. 8. Patients with any diseases that increase the risk of bleeding (e.g. acute gastritis, duodenal ulcer, and so on).
9\. Patients smoked more than 5 cigarettes a day in the first 3 months of screening 10. Alcohol breath test were positive (blood-alcohol concentration\>0.0mg/100ml) , or have history of alcoholism (more than 14 units of alcohol every week, 1 unit is equal to 285ml of beer, 25ml of spririts, or 100ml of wine.
11\. Drug abuse screening were positive by urinalysis, or have a history of substance abuse or taken drugs last 3 years.
12\. Subjects (or his fere) have family planning in the next 3 months, or can't take effective contraceptive measures in the next 3 months.
13\. Female subjects during lactation, the quantitative of β-HCG exceed the upper limit of normal range.
14\. Donate blood or massive blood loss (\>450ml) in the first 3 months of screening.
15\. Taken any drugs that can inhibit the activity of liver enzyme in the first 28 days of screening, or taken the inhibitor or inducer of CYP3A4, P-gp, Bcrp, such as Itraconazole, Ketoconazole, Dronedarone.
16\. Taken any prescription drugs, OTC, vitamin products or Chinese herbal medicine in the first 14 days of screening.
17\. Special diets (e.g. pitaya, mango, pomelo) or strenuous exercise in the first 14 days of screening, or other factors to influence drug absorption, distribution, metabolism and excretion.
18\. Have attended clinical trial in the first 3 months of screening 19. The patient can't finish the study according to protocol requirements. 20. Acute disease or simultaneous medication between screening stage and the first time taking study drugs.
21\. Have consumed any alcoholic or caffeinated food or beverage such as chocolate and coffee in the first 48 hours of taking the study drug.
22\. Investigator believes other factors not suitable for testing.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yang Lin, M.D.
Role: PRINCIPAL_INVESTIGATOR
Beijing Anzhen Hospital
Shan Jing, M.D.
Role: PRINCIPAL_INVESTIGATOR
Beijing Anzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cspc Nbp Pharmaceutical.Co.Ltd
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EY20170502
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.